Related Experiment Video

Updated: Aug 30, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Inflammatory myoblastic tumor of the uterus and interleukin-6

Yoichi Azuno1, Ken Yaga, Yasuko Suehiro

  • 1Department of Internal Medicine, Yamaguchi Rosai Hospital, Onoda City, Japan. azuno@ymg.urban.ne.jp

American Journal of Obstetrics and Gynecology
|October 4, 2003
PubMed

Insights

An inflammatory myoblastic tumor of the uterus was successfully treated with surgery. This led to a rapid decrease in elevated interleukin-6 (IL-6) levels, confirming IL-6 overproduction as a key factor.

Area of Science:

  • Gynecologic Oncology
  • Oncologic Pathology
  • Immunology

Background:

  • Inflammatory myoblastic tumors (IMTs) are rare neoplasms with variable presentation.
  • Constitutional symptoms can be associated with IMTs, suggesting a systemic inflammatory component.
  • The role of specific cytokines, such as interleukin-6 (IL-6), in IMT pathogenesis requires further elucidation.

Observation:

  • A patient presented with an inflammatory myoblastic tumor of the uterus accompanied by constitutional symptoms.
  • Elevated serum levels of interleukin-6 (IL-6) were detected in the patient.
  • Surgical excision of the uterine tumor was performed.

Findings:

  • The surgical removal of the inflammatory myoblastic tumor resulted in complete cure.
  • Post-operative follow-up revealed a rapid normalization of previously elevated serum IL-6 levels.
  • Messenger RNA (mRNA) detection via reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry confirmed IL-6 overproduction by the tumor tissue.

Implications:

  • Surgical excision is a curative treatment for inflammatory myoblastic tumors of the uterus.
  • Interleukin-6 (IL-6) overproduction is implicated in the pathogenesis of uterine IMTs and associated constitutional symptoms.
  • Targeting IL-6 pathways may represent a future therapeutic strategy for related conditions.

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...